South Africa has become the first African country — and our medicines regulator the third worldwide — to register the revolutionary twice-a-year anti-HIV jab, lenacapavir (LEN). The shot could bring ...

(Yicai) Oct. 27 -- Gilead Sciences has benefited from China's accelerated regulatory reforms in granting market access for innovative drugs, with the country's pilot zones enabling near-simultaneous ...

The WLA Prize is an international science award established at the forum in 2021. It aims to recognize exceptional ...

Gilead Sciences approaches Q3 2025 results on October 30, hitting new highs and presenting Livdelzi data at The Liver Meeting ...

Nkarta CEO Paul Hastings recently spoke to the importance of the industry's collaborations with Chinese biopharma companies.

We asked five academics with expertise in sexual health, nutrition, psychiatry, bioethics and drug policy. Here’s what they said.

Patients with PD-L1-positive metastatic triple-negative breast cancer reported improved emotional function and pain with sacituzumab govitecan plus pembrolizumab compared with chemotherapy plus ...

A recently approved twice-yearly injection to prevent HIV may warrant a higher price, but thousands of dollars more?  CVS Caremark’s chief medical officer calls on Gilead Sciences to lower the $28,000 ...

Sacituzumab govitecan significantly improved survival outcomes for previously untreated, PD-L1-negative metastatic ...

Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.

In the latest trading session, Gilead Sciences (GILD) closed at $121.46, marking a -2.11% move from the previous day. This change lagged the S&P 500's 0.53% loss on the day. Elsewhere, the Dow lost 0.